Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2024 Jun 26;19(6):e0305072. doi: 10.1371/journal.pone.0305072

Modes of HIV transmission among young women and their sexual partners in Ukraine

Oleksandr Zeziulin 1,*, Maryna Kornilova 2, Alexandra Deac 3, Olga Morozova 4, Olga Varetska 2, Iryna Pykalo 1, Kostyantyn Dumchev 1
Editor: Justyna Dominika Kowalska5
PMCID: PMC11207155  PMID: 38923979

Abstract

Background

Ukraine has the second-largest HIV epidemic in Europe, with most new cases officially attributed to heterosexual transmission. Indirect evidence suggested substantial HIV transmission from people who inject drugs (PWID) to their sexual partners. This study examined the extent of heterosexual HIV transmission between PWID and non-drug-using adolescent girls and young women (AGYW).

Methods

A cross-sectional survey recruited AGYW diagnosed with heterosexually-acquired HIV between 2016 and 2019 in nine regions of Ukraine. AGYW were asked to identify and refer their sexual partners (‘Partners’), who subsequently underwent HIV testing, and, if positive, HCV testing. Both AGYW and Partners completed an interview assessing HIV risk behaviors prior to AGYW’s HIV diagnosis.

Results

In August-December 2020, we enrolled 321 AGYW and 64 Partners. Among the Partners, 42% either self-reported IDU or were HCV-positive, indicating an IDU-related mode of HIV transmission. PWID Partners were more likely to report sexually transmitted infections (STI) and had lower educational levels. Of the 62 women who recruited at least one Partner, 40% had a PWID Partner. Within this subgroup, there was a higher prevalence of STIs (52% vs. 24%) and intimate partner violence (36% vs. 3%). Condom use was less common (52% vs. 38% reporting never use), and frequent alcohol or substance use before sex was higher (48% vs 30%) among AGYW with PWID Partner, although this difference did not reach statistical significance. Notably, 52% of women were aware of their Partners’ IDU.

Conclusion

At least 40% of heterosexual transmission among AGYW in Ukraine can be linked to PWID partners. Intensified, targeted HIV prevention efforts are essential for key and bridge populations (PWID and their sexual partners), addressing the biological and structural determinants of transmission between key and bridge populations, such as IDU- and HIV status disclosure, STIs, IPV, and stigma.

Introduction

Despite the substantial progress in the fight against HIV/AIDS over the past three decades [1], people who inject drugs (PWID) and their sexual partners remain vulnerable, facing increased risks of contracting and transmitting HIV [2]. Current evidence suggests that HIV key populations, including PWID, and their sexual partners account for up to 65% of all new HIV infections worldwide [3]. PWID often engage in risky sexual practices, such as having unprotected sex or having multiple sexual partners, who are often non-PWID [4,5].

Ukraine has the second largest HIV epidemic in Europe, with an estimated 240,000 people living with HIV in 2020 [6]. Official case registration data indicate that heterosexual transmission has been the dominant mode in Ukraine since 2008 [7]. However, epidemiological investigations have revealed significant misclassification of transmission modes [8,9], with a subsequent survey suggesting that at least 55% of HIV cases registered between 2013 and 2015 were likely attributed to injecting drug use (IDU) [10]. From 2015 until 2019, the distribution of primary transmission categories remained relatively stable, confirming sustained transmission levels among PWID, and emphasizing the continued significance of heterosexual mode. Indirect evidence was indicating that heterosexual transmission among women in Ukraine remained primarily linked to PWID partners [1113], which may be particularly true for young women who do not inject drugs [14]. This evidence has guided Ukraine’s National HIV Program to maintain its focus on prevention programs targeting key populations (PWID, men who have sex with men, and commercial sex workers) as well as bridge populations (sexual partners of key populations) [15].

Adolescent girls and young women (AGYW) are at a higher risk of HIV transmission due to early sexual debut, unprotected sex, and having sexual partners who engage in high-risk behaviors such as drug use, underscoring prominent gender differences in contracting HIV [16,17]. Heterosexual AGYW face disproportional and multifaceted challenges in accessing HIV prevention programs, and barriers to HIV disclosure, testing and care due to psychosocial pressure and stigma [1820]. According to Spectrum model, approximately 2,200–3,500 AGYW lived with HIV in Ukraine in 2019 [6].

Despite these emerging concerns, significant gaps persist in epidemiological knowledge about the specific risk factors and patterns of HIV transmission from PWID to AGYW who do not inject drugs [21]. Given the lack of knowledge, this potentially important bridge population was mostly neglected by HIV prevention programs in Ukraine. This study aimed to investigate the extent to which heterosexually acquired HIV cases among AGYW can be linked to their sexual partners who injected drugs. These results will help to understand whether transmission beyond key and bridge populations is substantial and whether there is a risk of HIV epidemic generalization, providing pivotal information for prevention efforts.

Methods

Study population and recruitment

We adapted the methodology from the previous study to enroll a random sample of women living with HIV and assess their HIV risk factors [10]. We employed the index testing approach [22] to recruit and assess their sexual partners. The primary target population was women diagnosed with HIV between the ages of 15–25 years in 2016–2019, who were registered with heterosexual mode of transmission. To obtain nationally representative estimates, the study was conducted in nine (of 27) geographically and epidemiologically diverse regions of the country: 1) Northern regions: Kyiv city and Kyiv Oblast; 2) Eastern regions: Dnipro, Donetsk; 3) Southern regions: Odesa, Mykolaiv 4) Central regions: Cherkasy, Zhytomyr 5) Western regions: Lviv, Volyn. The target sample size was distributed across these regions proportionally to the total number of HIV cases registered between 2016 and 2019.

Clinical staff at participating HIV clinics utilized the electronic HIV Medical Information System (MIS) to extract lists of IDs for women meeting the target population definition, stratified by year of diagnosis. Our study staff then performed random selection of the required number of patient IDs to achieve the target sample size (adjusted for non-response) for each site, and populated recruitment logs. Clinic staff used available information to contact the potential participants from the logs via phone or during clinical visits, read a standard invitation script, and scheduled study appointments at the clinic. After obtaining informed consent, participants were questioned about their history of IDU prior to HIV diagnosis and were tested for anti-HCV antibodies if previous test information was not available in the medical chart. Women who reported IDU or were HCV-positive were excluded from the study, as they were considered to have acquired HIV via parenteral mode.

The secondary study population was men who could potentially transmit HIV through sexual contact to participating AGYW. AGYW were requested to identify up to five men with whom they had sexual contacts before their HIV diagnosis and who could be a potential source of HIV infection (‘Partners’). For each Partner, women responded to three questions about history of intimate partner violence (IPV) or abuse (S1 Table). Those who met at least one ‘unsafe’ criterion were excluded from enrollment. For eligible Partners, women could choose either to refer them themselves using coupons or opt for referral by study staff. The process of status disclosure (if necessary) and referral was conducted according to the index testing guidelines [22]. Partners who arrived at the study site were screened to match the visual description provided by the referee. If matched, they were asked about HIV status. Those who knew about their status were verified using MIS, and those with negative or unknown status were tested for HIV. Those testing negative were excluded from the study. Men who tested positive for the first time or were not registered in HIV care were referred to HIV clinic staff for counseling and appropriate services, and later returned to the study.

Data collection

Both participant groups completed a self-administered assisted survey using REDCap electronic data capture tools [23] hosted at European Institute of Public Health Policy (Kyiv, Ukraine). The questionnaire assessed HIV risk factors that took place before the AGYW HIV diagnosis (including sexual behavior, drug and alcohol use, sexually transmitted infections (STI) history, parenteral exposures), self-reported way of HIV acquisition, and demographical information. We also collected data from MIS on the registered mode of HIV transmission and HCV status of the Partners. Partners who did not have data on HCV in their medical record, were tested for anti-HCV antibodies before the survey using a rapid test kit available at the clinic.

Data analysis

Frequencies and proportions for sociodemographic and behavioral variables were used to characterize the sampled participants separately for AGYW and Partners. We used logical formulas for risk behavior definitions of HIV risk factors (heterosexual, homosexual, injecting drug use, nosocomial, accidental and sexually transmitted infections; S2 Table). These variables were treated as not mutually exclusive, recognizing that individuals might be exposed to more than one factor simultaneously. In Partners, anti-HCV positivity was considered a marker of IDU exposure due the high parenteral transmissibility [24], low likelihood of sexual transmission [25], and relatively low prevalence in general population in Ukraine [26].

For Partners, we constructed a summary variable representing the most probable mode of transmission based on the survey responses (survey-based mode of HIV transmission, SMoT), based on the previous study approach [10]. If IDU risk factor was present (self-reported or assumed due to HCV positivity), SMoT was assigned as IDU. Men who had no IDU but reported male-to-male sex, were considered to be infected through MSM exposure. Others were assigned heterosexual SMoT.

We compared AGYW who had a Partner with IDU SMoT with those who did not. The differences in socio-demographic and HIV risk characteristics were assessed using chi-square and Fischer’s exact test for subtables with expected counts less than 5. A similar approach was used to compare Partners with or without IDU SMoT. To assess the extent of selection bias, we conducted a sensitivity analysis comparing women who had at least one Partner recruited to those who had not.

Statistical analyses were done using R version 4.3.2 [27].

Ethical statement

The Institutional Review Board (IRB) approved the study protocol at the Ukrainian Institute on Public Health Policy (Kyiv, Ukraine). Approval number: #28-20/IRB. All data collected were kept secure and accessible only to authorized research team members. Strict adherence to confidentiality was kept at all times. Written informed consent was obtained from all study participants. All participants were compensated for time spent on the study.

Results

A total of 321 AGYW with a likely heterosexual mode of HIV transmission were enrolled during the study enrollment period from August to December 2020 (Table 1). Median age at the time of diagnosis was 23 (IQR 21–24) years old, while median age at the time of the survey was 25 (IQR 23–27). Socio-demographic characteristics and HIV risk factors of AGYW are presented in Table 1.

Table 1. Socio-demographic characteristics and HIV risk factors of AGYW in the study sample.

    N %
Total 321 100.0
Age at the survey <20 12 3.7
  20–24 142 44.2
  25+ 167 52.0
Age at HIV registration <20 62 19.3
  20–24 228 71.0
  25 31 9.7
Education school 180 56.1
  technical 92 28.7
  higher 49 15.3
Employment employed 166 51.7
  unemployed 70 21.8
  student 59 18.4
  other 26 8.1
Family status single 229 71.3
  married 85 26.5
  separated 7 2.2
Time from testing to registration <3 months 196 81.7
  3–11.99 months 25 10.4
  12+ months 19 7.9
Time in care <1 year 28 8.7
  1–1.99 years 76 23.7
  2–2.99 years 85 26.5
  3+ years 132 41.1
Condom use never/rarely 129 40.2
  50/50 108 33.6
  often/always 84 26.2
Alcohol/substance use before sex never 50 15.6
  sometimes 165 51.4
  often/always 106 33.0
Attended places where others used drugs no 295 91.9
  yes 26 8.1
STI history no 233 72.6
  yes 88 27.4
Nosocomial exposure no 188 58.6
  yes 133 41.4
Accidental exposure no 250 77.9
  yes 71 22.1
Sex with male PWID no 259 80.7
  yes 62 19.3
Sex with MSM no 318 99.1
  yes 3 0.9
Sex with male PLWH no 133 41.4
  yes 188 58.6
Sex with male sex worker no 314 97.8
  yes 7 2.2
Selling sex for money no 311 96.9
  yes 10 3.1
History of IPV with named partners no 280 87.2
  yes 41 12.8

AGYW, adolescent girls and young women; STI, sexually transmitted infection; PWID, people who inject drugs; MSM, men who have sex with men; PLWH, people living with HIV, IPV, intimate partner violence.

Nearly 60% of women reported sexual contacts with men living with HIV before finding out about their own HIV status, and 19% reported having sex with men who injected drugs according to their knowledge. Only 26% used condoms regularly, and 33% often used alcohol or drugs before sex. Selling sex for money was reported by 3% of women, and 27% had at least one sexually transmitted infection.

Nearly all (314/321, 98%) of women were able to name and describe at least one partner who could be a potential source of heterosexual HIV transmission, 83% had at least one ‘safe’ partner without IPV or abuse history, and 38% agreed to refer partners for the study (S1 Table). A total of 66 Partners of 62 AGYW were successfully recruited, two tested negative for HIV and were excluded.

Most Partners were about 30 years old at the time of the survey (median 30, IQR 27–33). Fifty-one (80%) were already registered in HIV clinic with median time in care of 38 months (IQR 22–51); others tested positive during the survey. Sixteen (31%) were registered with IDU MoT, and 21 (33%) tested positive for anti-HCV (Table 2). In the survey, 25 (39%) self-reported any IDU history, and 2 (3%) reported male-to-male sex. Combined, these variables resulted in 27 (42%) of Partners assigned with IDU, 1 (2%) with MSM, and 36 (56%) with heterosexual SMoT. Among those already registered in care, the proportion of IDU SMoT was 45% (23/51). In comparison, Partners with IDU SMoT were less educated, had higher probability of nosocomial and accidental exposure, more likely had sex with women who injected drugs, and much higher frequency of STI history (Table 2).

Table 2. Socio-demographic characteristics and HIV risk factors of Partners, by SMoT.

SMoT
Total IDU Not IDU Chi-sq. p-value
N Col. % N Col. % N Col. %
Total (Row %) 64 100.0 27 42.2 37 57.8    
Age at the survey <30 27 44.3 11 44.0 16 44.4 F 0.794
  30–34 22 36.1 10 40.0 12 33.3    
  35+ 12 19.7 4 16.0 8 22.2    
Age at HIV registration <25 17 35.4 7 33.3 10 37.0 F 0.809
  25–29 20 41.7 10 47.6 10 37.0    
  30+ 11 22.9 4 19.0 7 25.9    
Education school 24 37.5 13 48.1 11 29.7 7.82 0.020
  technical 27 42.2 6 22.2 21 56.8    
  higher 13 20.3 8 29.6 5 13.5    
Employment employed 55 85.9 22 81.5 33 89.2 F 0.636
  unemployed 6 9.4 3 11.1 3 8.1    
  other 3 4.7 2 7.4 1 2.7    
Family status single 44 68.8 19 70.4 25 67.6 F 0.380
  married 14 21.9 7 25.9 7 18.9    
  separated 6 9.4 1 3.7 5 13.5    
Registered in HIV clinic no 13 20.3 4 14.8 9 24.3 0.38 0.536
  yes 51 79.7 23 85.2 28 75.7    
Time from testing to registration
<3 months 38 77.6 16 72.7 22 81.5 F 0.784
3–11.99 months 7 14.3 4 18.2 3 11.1    
12+ months 4 8.2 2 9.1 2 7.4    
Time in care <2 years 14 27.5 7 30.4 7 25.0 0.71 0.702
  2–3.99 years 21 41.2 8 34.8 13 46.4    
  4+ years 16 31.4 8 34.8 8 28.6    
Registered MoT IDU 16 31.4 16 69.6      
  heterosexual 35 68.6 7 30.4 28 100.0    
HCV test result neg 43 67.2 6 22.2 37 100.0    
  pos 21 32.8 21 77.8      
Self-reported IDU exposure no 39 60.9 2 7.4 37 100.0    
yes 25 39.1 25 92.6      
Homosexual exposure no 62 96.9 26 96.3 36 97.3 F 1.000
  yes 2 3.1 1 3.7 1 2.7    
STI history no 56 87.5 20 74.1 36 97.3 F 0.008
  yes 8 12.5 7 25.9 1 2.7    
Nosocomial exposure no 35 54.7 9 33.3 26 70.3 7.17 0.007
  yes 29 45.3 18 66.7 11 29.7    
Accidental exposure no 41 64.1 9 33.3 32 86.5 16.92 0.000
  yes 23 35.9 18 66.7 5 13.5    
Survey-based MoT heterosexual 36 56.3   36 97.3    
  IDU 27 42.2 27 100.0      
  MSM 1 1.6   1 2.7    
Sex with a woman who injects drugs  no 55 85.9 19 70.4 36 97.3 F 0.003
yes 9 14.1 8 29.6 1 2.7    
Sex with a woman living with HIV  no 38 59.4 19 70.4 19 51.4 1.62 0.203
yes 26 40.6 8 29.6 18 48.6    
Buying sex from women  no 46 71.9 22 81.5 24 64.9 1.39 0.239
yes 18 28.1 5 18.5 13 35.1    
Selling sex no 64 100.0 27 100.0 37 100.0    
Condom use never/rarely 33 51.6 13 48.1 20 54.1 4.05 0.132
  50/50 17 26.6 5 18.5 12 32.4    
  often/always 14 21.9 9 33.3 5 13.5    
Alcohol/substance use before sex  never/sometimes 18 28.1 8 29.6 10 27.0 0.00 1.000
often/always 46 71.9 19 70.4 27 73.0    

SMoT, survey-based mode of HIV transmission; MoT, mode of HIV transmission; IDU, injecting drug use; STI, sexually transmitted infection; MSM, men who have sex with men.

F denotes that Fischer’s exact test was used instead of chi-square test.

Among the 62 women who recruited at least one Partner, 25 (40.3%) had a Partner who likely acquired HIV through IDU (Table 3). AGYW who had a recruited Partner with IDU MoT exhibited a significantly higher frequency of STI (52% compared to 24% among those with non-IDU partners, p = 0.05). Notably, only 52% of AGYW with a IDU MoT Partner reported having sex with PWID, indicating low awareness of women about injecting behavior of their partners.

Table 3. Comparison of socio-demographic characteristics and HIV risk factors of AGYW, by Partners’ SMoT.

Partners’ SMoT
Total IDU Not IDU Chi-sq. p-value
N Col. % N Col. % N Col. %
Total (Row %) 62 100.0 25 40.3 37 59.7    
Age at the survey <20 1 1.6 1 4.0   F 0.418
  20–24 26 41.9 9 36.0 17 45.9    
  25+ 35 56.5 15 60.0 20 54.1    
Age at HIV registration <20 14 22.6 5 20.0 9 24.3 F 0.116
  20–24 42 67.7 15 60.0 27 73.0    
  25 6 9.7 5 20.0 1 2.7    
Education school 36 58.1 17 68.0 19 51.4 F 0.319
  technical 20 32.3 7 28.0 13 35.1    
  higher 6 9.7 1 4.0 5 13.5    
Employment employed 36 58.1 17 68.0 19 51.4 F 0.103
  unemployed 13 21.0 4 16.0 9 24.3    
  student 6 9.7   6 16.2    
  other 7 11.3 4 16.0 3 8.1    
Family status single 47 75.8 16 64.0 31 83.8 F 0.092
  married 14 22.6 8 32.0 6 16.2    
  separated 1 1.6 1 4.0      
Time from testing to registration  <3 months 40 88.9 7 87.5 33 89.2 F 0.643
3–11.99 months 2 4.4   2 5.4    
12+ months 3 6.7 1 12.5 2 5.4    
Time in care <1 year 5 8.1 2 8.0 3 8.1 F 0.757
  1–1.99 years 14 22.6 4 16.0 10 27.0    
  2–2.99 years 21 33.9 10 40.0 11 29.7    
  3+ years 22 35.5 9 36.0 13 35.1    
Condom use never/rarely 27 43.5 13 52.0 14 37.8 1.24 0.539
  50/50 21 33.9 7 28.0 14 37.8    
  often/always 14 22.6 5 20.0 9 24.3    
Alcohol/substance use before sex
never 7 11.3 1 4.0 6 16.2 F 0.213
sometimes 32 51.6 12 48.0 20 54.1    
often/always 23 37.1 12 48.0 11 29.7    
Attended places where others used drugs  no 56 90.3 23 92.0 33 89.2 F 1.000
yes 6 9.7 2 8.0 4 10.8    
STI history no 40 64.5 12 48.0 28 75.7 3.86 0.050
  yes 22 35.5 13 52.0 9 24.3    
Nosocomial exposure no 38 61.3 12 48.0 26 70.3 2.25 0.134
  yes 24 38.7 13 52.0 11 29.7    
Accidental exposure no 52 83.9 22 88.0 30 81.1 F 0.726
  yes 10 16.1 3 12.0 7 18.9    
Sex with male PWID no 48 77.4 12 48.0 36 97.3 18.02 0.000
yes 14 22.6 13 52.0 1 2.7
Sex with MSM no 61 98.4 25 100.0 36 97.3 F 1.000
  yes 1 1.6   1 2.7    
Sex with male PLWH no 14 22.6 3 12.0 11 29.7 1.76 0.184
  yes 48 77.4 22 88.0 26 70.3    
Sex with male sex worker no 60 96.8 25 100.0 35 94.6 F 0.511
  yes 2 3.2   2 5.4    
Selling sex for money no 55 88.7 22 88.0 33 89.2 F 1.000
  yes 7 11.3 3 12.0 4 10.8    
History of IPV with named partners  no 52 83.9 16 64.0 36 97.3 F 0.001
yes 10 16.1 9 36.0 1 2.7    

SMoT, survey-based mode of HIV transmission; IDU, injecting drug use; AGYW, adolescent girls and young women; STI, sexually transmitted infection; PWID, people who inject drugs; MSM, men who have sex with men; PLWH, people living with HIV, IPV, intimate partner violence.

F denotes that Fischer’s exact test was used instead of chi-square test.

Women with an IDU MoT Partner were much more likely to report IPV with either of the named partners (36% vs 3%, p = 0.001). Sexual contacts with men with known HIV status was very high in both groups (88% and 70%), although the difference was not significant. Sex with MSM, and buying sex from a male sex worker was rare and did not differ significantly. Selling sex for money was reported on average by 11% and did not differ between subgroups. Condom use was lower (52% vs 38% never used), and frequent alcohol or substance use before sex was more prevalent (48% vs 30%) among AGYW with an IDU MoT Partner, but these differences did not reach statistical significance.

The sensitivity analysis, comparing women who had a recruited Partner in the study (N = 62) with those who had not (N = 259), revealed that the groups were similar (S3 Table). No differences were observed in socio-demographic characteristics or risk practices. STI history was higher among those who had a Partner (36% vs 26%), but the difference was not significant. Women with PWID Partners were more likely to engage in sex sork (11% vs 1%, p = 0.001). Reports of IPV were similar between the two groups, with 16% and 12% respectively, without statistical difference. Importantly, sexual contacts with men living with HIV was 77% among AGYW with a Partner and 54% among those without one (p = 0.001), while any sex with male PWID was 19% on average without a notable difference between the subgroups.

Discussion

In this study we explored the extent to which heterosexual HIV transmission among non-PWID adolescent girls and young women in Ukraine is linked to the epidemic among PWID. Our approach involved recruiting sexual partners of AGYW and assessing their probable mode of transmission. The key findings was that at least 40% of heterosexually-infected AGYW could acquire HIV from PWID sexual partners, suggesting that the complex interplay between drug use and sexual behavior in key and bridge populations continues to be the driving force of the HIV epidemic in Ukraine.

Importantly, only about half or women with a Partner likely infected via IDU were aware of their partner’s injecting behavior. This may have important implications for personal risk perception and condom use [28], which should be taken into account in prevention programs targeting this bridge population. Additionally, this highlights that self-reported information from women about drug use of their partners may not accurately reflect their belonging to the bridge population.

Our results indicate that having a PWID Partner was associated with a higher frequency of STI, thereby increasing the probability of acquiring HIV through sexual contact [29]. Other factors that may further impact vulnerability to HIV, namely serodiscordant sexual relationships and condomless sex were also more prevalent among AGYW-partners of PWID, although the study did not have sufficient power to reach significance. These findings alight with existing evidence demonstrating elevated HIV risk among sexual partners of PWID in various cultural and economic contexts [30,31]. Transmission of HIV and other STIs from PWID to AGYW is substantially increased by psychosocial and structural factors, including unprotected sex, alcohol consumption, drug use, homelessness, stigma, and lack of awareness [32,33]. The importance of these factors is also confirmed in our comparison of PWID and non-PWID Partners, showing that the former group had a lower educational level and a higher risk of STIs.

Another important finding was that while 13% of all AGYW reported history of IPV with partners who could transmit HIV to them, women having a PWID Partner were twelve times more likely to report IPV than those with non-PWID sexual partners (36% compared to 3%). Worldwide IPV prevalence reaches up to 20% among women and varies across types of IPV (physical, psychological, and/or sexual), geographical locations and measurement purposes [34]. Although HIV-positive women appear to experience IPV at rates comparable to HIV-negative women from the same underlying populations, their abuse seems more frequent and severe [35]. This result highlights the multidimensional risk factors of heterosexual HIV transmission and underscores the need for integration of HIV prevention and IPV interventions among sexual partners of PWID [36].

As a secondary objective, we were able to assess the magnitude of misclassification of IDU MoT among Partners. The proportion of cases attributed to IDU was 31% in the official registration record, compared to 45% according to self-report in the survey combined with anti-HCV testing, indicating that approximately a third of IDU-transmitted cases are misclassified as heterosexual. This estimate is nearly identical to the one obtained in the previous survey in 2013–2015, although the proportion of IDU-related cases was notably higher at that time (70% among men) [10].

The current study adds to the literature, suggesting a significant association between injecting drug use, unprotected sex, and heterosexual transmission to non-drug-injecting women. Our findings highlight the need for tailored prevention interventions for serodiscordant couples and bridge populations (non-drug-using sexual partners of PWID), considering the complex interplay between HIV risks, IPV, STI, non-disclosure of HIV and IDU, and combined IDU- and HIV-related stigma to effectively address the unique challenges faced by PWID and their partners in Ukraine and beyond [37]. Additionally, such intervention could benefit from bottom-up approaches nested around lived experiences of AGYW in Ukraine to account for unstable socio-ecological environments (i.e., the ongoing war or pandemics) [3740].

Limitations

Our approach to identifying IDU exposure relied on participants’ self-report. Due to multiple forms of stigma [4143], it is likely that this behavior was underreported, particularly by women [42,44]. We used HCV seropositivity as a marker of drug injection, yet we cannot entirely exclude the possibility that some women in our sample were infected through IDU, and that the proportion of PWID among Partners was underestimated. This, however, lends confidence that our bridge population estimate (40%) represents a conservative minimum.

Another important limitation pertains to the relatively small number of enrolled Partners (n = 65). The response rate among partners was lower than expected, to a significant extent due to the COVID-19 pandemic and lockdown measures. These restrictions complicated our study enrollment, affecting public transportation and clinic attendance. We refrained from artificially increasing incentives to boost recruitment, as it could jeopardize the validity of index-partner relationships. The small sample size limits the precision and generalizability of our findings.

It is possible that the ability to enroll a Partner was not randomly distributed among women, introducing the possibility of selection bias. To address this concern, we conducted a sensitivity analysis, indicating that women who recruited a Partner were more aware of HIV status of their sexual contacts. This may result from our recruitment approach that excluded partners deemed ‘unsafe’ in terms of IPV. Other key characteristics of women did not differ, suggesting that the extent of this bias was moderate. Moreover, the exclusion of ‘unsafe’ partners further limits the generalizability of partner-related results and may contribute to the underestimation of the bridge population size.

Finally, due to the descriptive nature of the study, we did not perform in-depth analyses of causal relationships between the key independent variable (MoT of Partners) and potential outcomes. Therefore, the observed associations in both study groups can be explained by confounding due to measured or unmeasured factors.

Conclusion

Our study revealed that at least 40% of women who acquired HIV via heterosexual mode in 2016–2019 in Ukraine had a PWID sexual partner before seroconversion. This estimate underscores the significant contribution of this bridge population to the ongoing HIV epidemic in Ukraine. Women who had PWID partners also reported a higher prevalence of STI, low condom use, and significantly greater experience of IPV. These findings emphasize the need for intensified, targeted HIV prevention efforts among PWID and their sexual partners, particularly non-IDU AGYW. The prevention interventions and index testing strategies should comprehensively address the biological and structural determinants of transmission between key and bridge populations, such as IDU- and HIV status disclosure, STIs, IPV, and stigma. The ongoing large-scale index testing programs in Ukraine may provide additional data to assess the trends in transmission dynamics in key and bridge populations.

Supporting information

S1 Table. Partner recruitment status.

(DOCX)

pone.0305072.s001.docx (25.9KB, docx)
S2 Table. HIV risk factor definitions.

(DOCX)

pone.0305072.s002.docx (25.7KB, docx)
S3 Table. Comparison of socio-demographic characteristics and HIV risk factors of AGYW, by partner enrollment status.

(DOCX)

pone.0305072.s003.docx (34.2KB, docx)
S1 Data

(CSV)

pone.0305072.s004.csv (240.2KB, csv)
S2 Data

(CSV)

pone.0305072.s005.csv (16.9KB, csv)

Data Availability

All relevant data are within the manuscript and its Supporting Information files.

Funding Statement

The study was conducted under the financial support of International Charitable Foundation "Public Health Alliance" (hereinafter the Alliance) which is a leading professional organization that, in cooperation with key public organizations, the Ministry of Health and other government bodies of Ukraine, fights the HIV/AIDS epidemic in Ukraine, managing preventive programs and providing quality technical support and financial resources to organizations. The Alliance experts contributed to the study design and data analysis, decision to publish, and preparation of the manuscript.

References

  • 1.Global HIV & AIDS Statistics: 2020 Factsheet [Internet]. 2020. Available from: https://www.unaids.org/en/resources/fact-sheet. [Google Scholar]
  • 2.Jolley E RT, Platt L, Hope V, Latypov A, Donoghoe M, et al. HIV among people who inject drugs in Central and Eastern Europe and Central Asia: A systematic review with implications for policy. BMJ Open. 2012;2(5). doi: 10.1136/bmjopen-2012-001465 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.World Health Organization. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022–2030 2022. [Available from: https://www.who.int/publications/i/item/9789240053779. [Google Scholar]
  • 4.Tun W SM, Broz D, Okal J, Muraguri N, Raymond HF, et al. HIV and STI Prevalence and Injection Behaviors Among People Who Inject Drugs in Nairobi: Results from a 2011 Bio-behavioral Study Using Respondent-Driven Sampling. AIDS Behav. 2015;19(1). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Niccolai LM SI, Toussova O v., Kozlov AP, Heimer R. The potential for bridging of HIV transmission in the russian federation: Sex risk behaviors and hiv prevalence among drug users (DUs) and their non-du sex partners. Journal of Urban Health. 2009;86:131–43. doi: 10.1007/s11524-009-9369-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Public Health Center of the MoH of Ukraine. National Evaluation of HIV/AIDS Situation in Ukraine (as of beginning of 2022) Kyiv: PHC; 2022. [Available from: https://phc.org.ua/sites/default/files/users/user90/Natsionalna_otsinka_sytuatsyi_z_VIL_SNIDu_v_Ukraini_na_pochatok_2022.pdf. [Google Scholar]
  • 7.Public Health Center of the MoH of Ukraine. HIV infection in Ukraine Informational Bulletin #53 Kyiv2022 [Available from: https://phc.org.ua/kontrol-zakhvoryuvan/vilsnid/monitoring-i-ocinka/informaciyni-byuleteni-vilsnid. [Google Scholar]
  • 8.Cakalo JI, Bozicevic I, Vitek C, Mandel JS, Salyuk T, Rutherford GW. Misclassification of men with reported HIV infection in Ukraine. AIDS and behavior. 2015;19(10):1938–40. doi: 10.1007/s10461-015-1112-0 [DOI] [PubMed] [Google Scholar]
  • 9.Spindler H, Salyuk T, Vitek C, Rutherford G. Underreporting of HIV transmission among men who have sex with men in the Ukraine. AIDS research and human retroviruses. 2014;30(5):407–8. doi: 10.1089/aid.2013.0237 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Dumchev K, Kornilova M, Kulchynska R, Azarskova M, Vitek C. Improved ascertainment of modes of HIV transmission in Ukraine indicates importance of drug injecting and homosexual risk. BMC public health. 2020;20(1):1288. doi: 10.1186/s12889-020-09373-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Abdul-Quader A DK, Kruglov Y, Rutherford GW, Salyuk T, Vitek C. Ukraine HIV Data Synthesis Project. University of California, San Francisco: Institute for Global Health; 2012. [Google Scholar]
  • 12.Vitek CR, Cakalo JI, Kruglov YV, Dumchev KV, Salyuk TO, Bozicevic I, et al. Slowing of the HIV epidemic in Ukraine: evidence from case reporting and key population surveys, 2005–2012. PloS one. 2014;9(9):e103657. doi: 10.1371/journal.pone.0103657 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.UNAIDS. Global AIDS Monitoring 2019: Ukraine 2020. [Available from: https://www.unaids.org/sites/default/files/country/documents/UKR_2020_countryreport.pdf. [Google Scholar]
  • 14.Toussova O SI, Volkova G, Niccolai L, Heimer R, Kozlov A. Potential bridges of heterosexual HIV transmission from drug users to the general population in St. Petersburg, Russia: is it easy to be a young female. J Urban Health. 2009;86:121–30. doi: 10.1007/s11524-009-9364-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Ukraine MoHo. Prevention of HIV infection, diagnosis, treatment and care for key population groups: Evidence-based clinical guidelines. 2018. [Google Scholar]
  • 16.Mathur S, Pilgrim N, Patel SK, Okal J, Mwapasa V, Chipeta E, et al. HIV vulnerability among adolescent girls and young women: a multi-country latent class analysis approach. International Journal of Public Health. 2020;65(4):399–411. doi: 10.1007/s00038-020-01350-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Cheuk E, Mishra S, Balakireva O, Musyoki H, Isac S, Pavlova D, et al. Transitions: Novel Study Methods to Understand Early HIV Risk Among Adolescent Girls and Young Women in Mombasa, Kenya, and Dnipro, Ukraine. Frontiers in reproductive health. 2020;2:7. doi: 10.3389/frph.2020.00007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Ahn J V. BH, Malyuta R, Volokha A, Thorne C. Factors Associated with Non-disclosure of HIV Status in a Cohort of Childbearing HIV-Positive Women in Ukraine. AIDS Behav. 2016;20(1):174–83. [DOI] [PubMed] [Google Scholar]
  • 19.Corsi KF DS, Garver-Apgar C, Davis JM, Brewster JT, Lisovska O, et al. Gender differences between predictors of HIV status among PWID in Ukraine. Drug Alcohol Depend. 2014;138(1). doi: 10.1016/j.drugalcdep.2014.02.012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Dethier D, Rybak N, Hirway P, Bachmaha M, Carroll J, Sorokolit A ea. The changing face of women living with HIV in western Ukraine. Int J STD AIDS. 2018;29(4). doi: 10.1177/0956462417724708 [DOI] [PubMed] [Google Scholar]
  • 21.Vitek CR CJ, Kruglov Y v, Dumchev K v, Salyuk TO, Bozicevic I, et al. Slowing of the HIV epidemic in Ukraine: evidence from case reporting and key population surveys: 2005–2012. PLoS ONE. 2014;9(9). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.PEPFAR. PEPFAR Guidance on Implementing Safe and Ethical Index Testing Services 2020. [Available from: https://www.state.gov/pepfar-guidance-on-implementing-safe-and-ethical-index-testing-services/. [Google Scholar]
  • 23.Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019;95:103208. doi: 10.1016/j.jbi.2019.103208 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Des Jarlais DC, Arasteh K, McKnight C, Hagan H, Perlman D, Friedman SR. Using hepatitis C virus and herpes simplex virus-2 to track HIV among injecting drug users in New York City. Drug and alcohol dependence. 2009;101(1–2):88–91. doi: 10.1016/j.drugalcdep.2008.11.007 [DOI] [PubMed] [Google Scholar]
  • 25.Terrault NA, Dodge JL, Murphy EL, Tavis JE, Kiss A, Levin TR, et al. Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. Hepatology. 2013;57(3):881–9. doi: 10.1002/hep.26164 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Hope VD, Eramova I, Capurro D, Donoghoe MC. Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association. Epidemiology and infection. 2014;142(2):270–86. doi: 10.1017/S0950268813000940 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.R Core Team. R: A language and environment for statistical computing: R Foundation for Statistical Computing, Vienna, Austria.; 2023. [Available from: https://www.R-project.org/. [Google Scholar]
  • 28.Schaefer R, Thomas R, Maswera R, Kadzura N, Nyamukapa C, Gregson S. Relationships between changes in HIV risk perception and condom use in East Zimbabwe 2003–2013: population-based longitudinal analyses. BMC public health. 2020;20(1):756. doi: 10.1186/s12889-020-08815-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Hayes R, Watson-Jones D, Celum C, van de Wijgert J, Wasserheit J. Treatment of sexually transmitted infections for HIV prevention: end of the road or new beginning? Aids. 2010;24 Suppl 4(0 4):S15–26. doi: 10.1097/01.aids.0000390704.35642.47 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Abdul Manaf R. HIV risk and preventive behaviours among the intimate partners of men who inject drugs in Malaysia (Thesis, Doctor of Philosophy). 2015.
  • 31.El-Bassel N SS, Dasgupta A, Strathdee SA. People Who Inject Drugs in Intimate Relationships: It Takes Two to Combat HIV. Curr HIV/AIDS Rep. 2014;11(1). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Riehman KS WW, Francis SA, Moore M, Morgan-Lopez A. Discordance in monogamy beliefs, sexual concurrency, and condom use among young adult substance-involved couples: Implications for risk of sexually transmitted infections. Sex Transm Dis. 2006;33(11). doi: 10.1097/01.olq.0000218882.05426.ef [DOI] [PubMed] [Google Scholar]
  • 33.Witte Susan S, Nabila El-Bassel, Louisa Gilbert, Elwin Wu, Chang M. Lack of awareness of partner STD risk among heterosexual couples. Perspectives on sexual and reproductive health. 2010;42(1):49–55. doi: 10.1363/4204910 [DOI] [PubMed] [Google Scholar]
  • 34.Román-Gálvez RM M-PS, Fernández-Félix BM, Zamora J, Khan KS, Bueno-Cavanillas A. Worldwide Prevalence of Intimate Partner Violence in Pregnancy. A Systematic Review and Meta-Analysis. Frontiers in Public Health. 2021;9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Gielen AC GR, Burke JG, Mahoney P, McDonnell KA, O’Campo P. HIV/AIDS and intimate partner violence: intersecting women’s health issues in the United States. Trauma Violence Abuse. 2007;8(2):178–98. doi: 10.1177/1524838007301476 [DOI] [PubMed] [Google Scholar]
  • 36.El-Bassel N GL, Terlikbayeva A, Beyrer C, Wu E, Shaw SA, et al. HIV risks among injecting and non-injecting female partners of men who inject drugs in Almaty, Kazakhstan: Implications for HIV prevention, research, and policy. International Journal of Drug Policy. 2014;25(6). doi: 10.1016/j.drugpo.2013.11.009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Blumer N, Pfadenhauer LM, J. B. Access to HIV-prevention in female sex workers in Ukraine between 2009 and 2017: Coverage, barriers and facilitators. PLoS ONE. 2021;16. doi: 10.1371/journal.pone.0250024 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.E. H. Conflict in Ukraineand a ticking bomb of HIV. The Lancet. 2018;5. [DOI] [PubMed] [Google Scholar]
  • 39.E. H. Ukraine adapts its HIV response. The Lancet HIV. 2022;9 (11):E747–E8. [DOI] [PubMed] [Google Scholar]
  • 40.Iakunchykova OP V. B. Correlates of HIV and Inconsistent Condom Use Among Female Sex Workers in Ukraine. AIDS Behav. 2017;1(21):2306–15. doi: 10.1007/s10461-016-1495-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Earnshaw VA, Smith LR, Cunningham CO, MM C. Intersectionality of internalised HIV stigma and internalised substance use stigma: Implications for depressive symptoms. J Health Psychol. 2015;20(8). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Owczarzak J FS, Coyle C, Davey-Rothwell M, Kiriazova T, Tobin K. The Relationship Between Intersectional Drug Use and HIV Stigma and HIV Care Engagement Among Women Living with HIV in Ukraine. AIDS Behav. 2023;27(6):1914–25. doi: 10.1007/s10461-022-03925-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Sereda Y, Kiriazova T, Makarenko O, Carroll JJ, Rybak N, Chybisov A, et al. Stigma and quality of co-located care for HIV-positive people in addiction treatment in Ukraine: a cross-sectional study. Journal of the International AIDS Society. 2020;23(5):e25492. doi: 10.1002/jia2.25492 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Deryabina AP, Patnaik P, WM E-S. Underreported injection drug use and its potential contribution to reported increase in sexual transmission of HIV in Kazakhstan and Kyrgyzstan. Harm Reduct J. 2019;16(1):1. doi: 10.1186/s12954-018-0274-2 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Justyna Dominika Kowalska

21 Dec 2023

PONE-D-23-32276The modes of HIV transmission among young women registered in HIV clinics and their sexual partners in Ukraine.PLOS ONE

Dear Dr. Zeziulin,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Feb 04 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript

Kind regards,

Justyna Dominika Kowalska

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following financial disclosure:

“The study was conducted under the financial support of  International Charitable Foundation "Public Health Alliance" (hereinafter the Alliance) is a leading professional organization that, in cooperation with key public organizations, the Ministry of Health and other government bodies of Ukraine, fights the HIV/AIDS epidemic in Ukraine, managing preventive programs and providing quality technical support and financial resources to organizations.

All these efforts are aimed at achieving in the country universal access to comprehensive services for HIV/AIDS, tuberculosis and viral hepatitis C in Ukraine and an effective response to the epidemic at the community level, based on the achieved results and best practices. As an independent legal entity, registered in Ukraine since 2003 and after acquiring managerial independence since January 2009, the Alliance shares the values and remains a member of the global partnership of the Alliance for Public Health (an international charitable organization that unites 30 organizations from different countries, with the Secretariat in . Hove, UK).

The Alliance's mission is to reduce the spread of HIV infection and AIDS-related mortality and reduce the negative impact of the epidemic by supporting public response to the HIV/AIDS epidemic in Ukraine, as well as by spreading effective approaches to HIV prevention and treatment in Eastern Europe and Central Asia.

The main programs currently carried out by the Alliance are:

• the "Investment in Impact on Tuberculosis and HIV" program, financed by the Global Fund to Fight AIDS, Tuberculosis and Malaria;

• the program "Improving the cascade of HIV treatment for key population groups by means of differentiated detection of new cases and involvement in treatment, building the potential of the Public Health Center of the Ministry of Health of Ukraine and strategic information in Ukraine", financed as part of the METIDA international technical assistance project;

• others.

This procurement of this study was carried out under the project "Accelerating progress in reducing the burden of tuberculosis and HIV infection by providing universal access to timely and high-quality diagnosis and treatment of tuberculosis, expansion of evidence-based prevention, diagnosis and treatment of HIV infection, creation of viable and stable health care systems ", with the support of the Global Fund.”

Please state what role the funders took in the study.  If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

If this statement is not correct you must amend it as needed.

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

3. In the online submission form, you indicated that [The data set contains sensitive information on the characteristics of peaple living with HIV and will be issued upon the official request to the Alliance for Public Health, Ukraine.].

All PLOS journals now require all data underlying the findings described in their manuscript to be freely available to other researchers, either 1. In a public repository, 2. Within the manuscript itself, or 3. Uploaded as supplementary information.

This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If your data cannot be made publicly available for ethical or legal reasons (e.g., public availability would compromise patient privacy), please explain your reasons on resubmission and your exemption request will be escalated for approval.

4. Please include your full ethics statement in the ‘Methods’ section of your manuscript file. In your statement, please include the full name of the IRB or ethics committee who approved or waived your study, as well as whether or not you obtained informed written or verbal consent. If consent was waived for your study, please include this information in your statement as well.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The title of the manuscript is acceptable and informative, the introduction reflects the purpose of the study - to investigate the role of the bridge populations in the HIV epidemic in Ukraine. Research approach and Enrollment methodology

correspond to the study hypotheses and are sufficienly detailed: assessment was based on measuring the point prevalence of Hepatitis C and IDU as outcomes and probable predictors in the target population to calculate statistical associations using Pearson’s chi-square test.

Research results based on analysis of available data, taking into account strengths and limitations

assessible, well substantiate the Conclusion and the importance of future studies.

The References list contains the most significant publications of recent years related to the research topic

Reviewer #2: The general comments to the paper are:

The paper describes a study investigating modes of HIV transmission in adolescent girls and young women in Ukraine and their links to PWID. I believe that this study addresses important questions, especially for an Eastern European country with the high prevalence of injecting drug use and HIV. The study utilizes both a survey and serological confirmatory testing, along with obtaining information from the national HIV database. The study participants were enrolled from nine different regions of Ukraine, which is a great strength considering the size of the country and the known disparity in healthcare, HIV prevalence, and economy between the regions.

I believe this paper will be of interest to readers, and I hope the comments below can improve it and eliminate the concerns that might arise.

I think that this paper could be substantially improved by shortening the Introduction section and focusing only on the most relevant findings of the previous studies.

It was not fully clear for me as a reader that the research question is the prevalence of HCV in partners of the AGYW enrolled in the study. A substantial emphasis is put on AGYW, the section on their partners in Result is the second one, and I only found that the main question was the prevalence of HCV in partners, from Supplementary 2. The authors might consider reshaping the paper by starting the Results section from the merged Table 1 including both AGYW and their partners, then going by the order of their hypotheses as they were listed in Supplementary 3.

I would suggest to also emphasize the main research question more in Discussion. I believe there is room for comparison also with non-Eastern European studies, especially given that the authors want to stress the role of stigma in IDU underreporting and the higher barriers to accessing care in Ukraine.

I would advise the authors to check the paper against the People First Chapter terminology guidance, specifically avoiding such words as “HIV-infected” or “having HIV seropositive status” which can be replaced by “living with HIV” (https://peoplefirstcharter.org/#:~:text=The%20People%20First%20Charter%20was,language%20perpetuates%20stigma%20%26%20marginalises%20people)

I believe some check of the references is needed; in a couple of places, the information in the paper does not match the data in the references.

I also believe this paper could be slightly improved also in terms of the language and grammar; currently, there are some places where the meaning of the text is unclear, and where the language check will improve the readability.

More specific comments by section are provided in the attached document.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Nataliya Nizova Ph.D. M.D. Professor

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: Review_PWID and AGYW in Ukraine.docx

pone.0305072.s006.docx (27.5KB, docx)
PLoS One. 2024 Jun 26;19(6):e0305072. doi: 10.1371/journal.pone.0305072.r002

Author response to Decision Letter 0


19 Mar 2024

We thank the Reviewers and Editors for a thoughtful and detailed review and, agreeing with the comments, have revised the manuscript significantly.

1. We revised financial disclosure.

2. We included study data sets as supplementary information.

3. We included full ethics statement in the ‘Methods’ section of the manuscript

Attachment

Submitted filename: Response to Reviewers.docx

pone.0305072.s007.docx (37.7KB, docx)

Decision Letter 1

Justyna Dominika Kowalska

23 May 2024

Modes of HIV transmission among young women and their sexual partners in Ukraine.

PONE-D-23-32276R1

Dear Dr. Oleksandr Zeziulin,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Justyna Dominika Kowalska

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors carefully and creatively worked on the comments, which seriously strengthened the evidence of the research hypothesis and the validity of the conclusions.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Nataliya Nizova

**********

Acceptance letter

Justyna Dominika Kowalska

18 Jun 2024

PONE-D-23-32276R1

PLOS ONE

Dear Dr. Zeziulin,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Justyna Dominika Kowalska

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. Partner recruitment status.

    (DOCX)

    pone.0305072.s001.docx (25.9KB, docx)
    S2 Table. HIV risk factor definitions.

    (DOCX)

    pone.0305072.s002.docx (25.7KB, docx)
    S3 Table. Comparison of socio-demographic characteristics and HIV risk factors of AGYW, by partner enrollment status.

    (DOCX)

    pone.0305072.s003.docx (34.2KB, docx)
    S1 Data

    (CSV)

    pone.0305072.s004.csv (240.2KB, csv)
    S2 Data

    (CSV)

    pone.0305072.s005.csv (16.9KB, csv)
    Attachment

    Submitted filename: Review_PWID and AGYW in Ukraine.docx

    pone.0305072.s006.docx (27.5KB, docx)
    Attachment

    Submitted filename: Response to Reviewers.docx

    pone.0305072.s007.docx (37.7KB, docx)

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting Information files.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES